Advertisements

Cilaxoral

Quick links to important sections

Cilaxoral

Advertisements
Advertisements

Method of action: Laxative

Treatment option: Constipation, Proctitis

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Cilaxoral

What is Cilaxoral? Definitive Overview

Property Description
Active ingredient Sodium Picosulfate
Form Oral solution, drops, and tablets
Pharmacological class Stimulant Laxative (Contact Laxative)
Common use Promoting bowel movement
Origin Synthetic triarylmethane derivative

Defining the Medicinal Entity and Classification

Cilaxoral is a trade name for a medicinal product containing the active substance Sodium Picosulfate, which is classified chemically as a synthetic triarylmethane derivative. This compound is strictly categorized as a stimulant laxative, or more specifically, a contact laxative, a class whose action is recognized for its predictable effect on the large intestine. This categorization serves to distinguish it from bulk-forming or osmotic agents. The product is formulated for oral administration and is available in forms such as oral solution (drops) and tablets, often sold as an Over-The-Counter (OTC) medicine depending on local regulations.

Form, Composition, and Unique Action

The active ingredient, Sodium Picosulfate, functions as a prodrug; it is inert until converted by the natural bacterial flora of the colon into the active compound, BHPM (bis-(p-hydroxyphenyl)-2-pyridylmethane). This unique mechanism ensures that the stimulus is applied precisely in the large intestine, minimizing systemic absorption. This localized action is characteristic of its design for targeted relief as a cathartic agent.

General Therapeutic Purpose

As a stimulant laxative, the general purpose of Cilaxoral is to provide focused assistance in promoting bowel movement and correcting occasional sluggish bowel function. Its mechanism works by accelerating the wave-like muscular contractions (peristalsis) while encouraging water retention in the colon. Together, these actions provide the high-level benefit of reliably facilitating the passage of material and contributing to a satisfactory bowel evacuation.

Advertisements

What side effects are possible with Cilaxoral?

Adverse Reaction Scope

Adverse reactions associated with laxative drug products, as regulated by governmental authorities, primarily affect the gastrointestinal system, renal function, and metabolism/nutrition.

Key concerns involve potential serious adverse reactions that have led to specific regulatory warnings. These include:

  • Esophageal obstruction and choking, which are documented risks for bulk-forming agents if taken without adequate fluid.
  • Acute kidney injury and renal failure, particularly linked to oral sodium phosphate products, with some cases resulting in permanent renal impairment.
  • Serious fluid and electrolyte adverse effects (e.g., severe dehydration or imbalance of sodium, calcium, or phosphate), which can lead to complications such as cardiac arrhythmias and seizures.
Classification Examples of Adverse Events
Common (based on similar drug classes) Diarrhea, abdominal pain, bloating, flatulence, nausea.
Serious / Clinically Significant Esophageal obstruction, acute kidney injury, renal failure, severe electrolyte imbalance, signs of allergic reaction.

Safety Classifications and Restrictions

Regulatory warnings emphasize the critical importance of adhering to dosing limits. The U.S. Food and Drug Administration (FDA) requires the following safety considerations:

  • Dose-Related Pattern: Using more than the maximum recommended dose in a 24-hour period for certain osmotic laxatives can cause rare but serious harm to the kidneys and heart. Even if no bowel movement occurs, a second dose must not be taken within the 24-hour period.
  • Population-Specific Considerations: Patients over 55, or those with existing kidney disease, heart failure, or bowel obstruction, are at increased risk for harmful side effects and should be monitored closely.
  • Safety-Related Restrictions: Specific product types require a formal Boxed Warning to advise of the risk of acute phosphate nephropathy. Bulk-forming agents are contraindicated in individuals with difficulty swallowing and require mandatory directions for mixing with sufficient fluid to prevent obstruction.
Advertisements

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Cilaxoral (Sodium Picosulfate) defines overdose primarily by its gastrointestinal and resulting systemic effects.


Documented Overdose Manifestations

Acute overdose is documented to present with severe profuse diarrhoea and intense abdominal cramps. The most significant immediate consequence is the resulting loss of fluid and electrolytes, notably potassium (hypokalaemia), leading to potential dehydration. Chronic overdosage or long-term abuse is associated with more severe, systemic complications including metabolic alkalosis, secondary hyperaldosteronism, and documented risks of renal tubular damage and colonic mucosal ischaemia.


Mandated Emergency Action and Management

Regulatory guidance is explicit that if an overdose is suspected, the individual must seek immediate medical attention, go to a hospital straight away, or contact a poison control center at once. No specific antidote is known for Cilaxoral.

Management consists of general supportive measures, with the primary focus on maintenance of fluid intake and the required replacement and correction of electrolyte imbalance. This fluid and electrolyte management is documented as especially important in the elderly and the young, who are more susceptible to severe dehydration. Close patient monitoring is required throughout the process.

Advertisements

Therapeutic Uses of Cilaxoral

Main Uses and Therapeutic Intent

Cilaxoral is a pharmacological treatment primarily indicated for the management of chronic constipation and certain functional bowel disorders. Its therapeutic objective is to restore regular bowel movements and improve the consistency of stools in individuals who have not achieved adequate relief through dietary modifications or lifestyle changes.

Chronic Idiopathic Constipation

The primary use of Cilaxoral is for chronic idiopathic constipation (CIC). This condition is characterized by persistent difficulty in passing stool or infrequent bowel movements that do not have an underlying identified anatomical or physiological cause. Cilaxoral works by facilitating the movement of waste through the gastrointestinal tract, thereby increasing the frequency of bowel movements.

Irritable Bowel Syndrome with Constipation

Cilaxoral is also utilized in the management of Irritable Bowel Syndrome with Constipation (IBS-C). In this context, the medication addresses a complex of symptoms including:

  • Abdominal discomfort or pain associated with bowel habits.
  • Bloating and a sensation of incomplete evacuation.
  • Strained or infrequent bowel movements.

Benefits and Clinical Impact

The benefits of Cilaxoral focus on the symptomatic relief of gastrointestinal distress and the normalization of digestive transit times.

Improvement of Stool Consistency

By influencing the fluid dynamics within the intestinal lumen, Cilaxoral helps to soften the stool. This reduces the physical strain required during defecation and decreases the discomfort associated with passing hard or dry stools.

Frequency and Regularity

Clinical application of Cilaxoral aims to establish a more predictable and frequent schedule of evacuation. This regularity is a key benefit for individuals whose daily activities are frequently interrupted by the unpredictability of chronic digestive issues.

Reduction of Abdominal Symptoms

Beyond the physical act of defecation, the medication helps alleviate secondary symptoms of constipation. This includes a reduction in the severity of abdominal bloating and the feeling of fullness or pressure that often accompanies slowed intestinal transit.

Regulatory References

  1. DailyMed NIH overview of Sodium Picosulfate Combination
Advertisements

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Cilaxoral — Official Regulatory Information

The eligibility profile for Cilaxoral (Sodium Picosulfate) is strictly defined by government regulatory documents, outlining who is approved for use and who is formally contraindicated.

Populations for Whom Use is Prohibited

Cilaxoral must not be used in patients presenting with several critical conditions. These include gastrointestinal obstruction or ileus, bowel perforation, toxic colitis, toxic megacolon, and severe dehydration. The medicine is also contraindicated for patients with severe reduced renal function (creatinine clearance less than 30 mL/minute) and a known hypersensitivity to any of its components.

Conditional Use and Age Restrictions

Use is restricted in certain age groups and clinical states. For pediatric patients, regulatory labels indicate that use is not established or not recommended for children under the age of 9 or 10 years, depending on the indication and region. Pregnancy and breastfeeding are conditional states: the medication should not be taken unless a healthcare provider determines the expected benefit clearly outweighs the possible risk. Caution is also advised for elderly patients and those with mild to moderate renal impairment or cardiac arrhythmia risk.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents describe interaction patterns for Cilaxoral (Sodium Picosulfate) primarily related to fluid and electrolyte balance and altered gastrointestinal transit time.

Interaction Type Interacting Substances/Products Official Effect Description
Pharmacodynamic Risk Diuretics, Adrenocorticosteroids Increased risk of hypokalemia (low potassium) due to additive effects on fluid excretion.
Toxicity Risk Cardiac Glycosides (e.g., Digoxin) Hypokalemia may increase the patient’s sensitivity and toxicity risk to these agents.
Absorption/Exposure General Oral Medications Reduced systemic exposure due to accelerated gastrointestinal transit, necessitating timing separation.
Reduced Efficacy Broad-Spectrum Antibiotics Potential to reduce the intended laxative action by suppressing the colonic bacteria necessary for prodrug activation.

Co-administration with other laxatives is prohibited, and the consumption of alcohol, solid food, or dairy products is officially restricted during the administration period. A mandatory timing rule requires that general oral medications not be administered within 1 hour of starting the laxative. Furthermore, specific agents such as Iron, Digoxin, and certain antibiotics require a separation of at least 2 hours before and not less than 6 hours after the product's administration. Caution is also advised for patients with impaired renal function who are taking medications that affect kidney function, such as ACE inhibitors or NSAIDs.

Advertisements

Mechanism of Action

Cilaxoral contains sodium picosulfate, an inactive prodrug that is non-absorbable in the small intestine. The compound is selectively accumulated in the colon, where it undergoes enzymatic cleavage. Colonic bacteria express the enzyme sulfatase, which hydrolyzes sodium picosulfate to form the pharmacologically active metabolite, bis-(p-hydroxy-phenyl)-pyridyl-2-methane (BHPM).

BHPM, a stimulant compound, interacts directly with the mucosal layer and sensory nerve endings within the colonic wall. This interaction modifies cellular signaling to promote a dual downstream cascade: stimulation of intestinal motility and modulation of water and electrolyte transport.

Specifically, BHPM acts as a contact laxative on the colonic mucosa, inducing peristalsis by increasing the frequency and force of smooth muscle contractions. Concurrently, it inhibits the absorption of water and electrolytes from the colonic lumen and increases their secretion into the lumen. This dual mechanism increases intraluminal fluid volume, resulting in system-level physiological modulation that accelerates colonic transit time and facilitates the passage of luminal content.

Advertisements

Dosage and Administration Information

How to use Cilaxoral: Official Administration Guidelines

Cilaxoral (Sodium Picosulfate) is administered via the oral route. Usage patterns vary significantly depending on the product formulation and the intended clinical application, which are strictly categorized as either short-term relief or pre-procedure bowel cleansing.


Administration Scope

Usage Entity Category Official Instructions (Label-Based)
Dosing Schedule For constipation, the maximum daily dose for adults and children aged 10 years and older is 10 mg, starting typically with 5 mg. For bowel cleansing, a two-dose regimen of the combination product is required.
Frequency and Timing For constipation, it is generally administered once daily at bedtime to align the 6- to 12-hour onset with the following morning. For cleansing, the two doses are separated by specific intervals, typically 5 to 6 hours, relative to the scheduled procedure.
Preparation Requirements Powder forms must be reconstituted immediately before use by dissolving completely in a specified volume of cold water (e.g., 150 mL), and are not to be prepared in advance.
Age-Group Rules Monotherapy for constipation is typically restricted to patients 10 years of age and older. The bowel cleansing regimen is approved for patients 9 years of age and older.

Procedural Conditions and Duration

Administration protocols require strict adherence. Use for short-term constipation relief must not exceed five consecutive days. For bowel cleansing, the entire course is a single, time-limited regimen. Adequate fluid intake is essential, and for bowel cleansing, the consumption of solid food is restricted during the preparation period.

Furthermore, concomitant oral medications should not be taken within 1 hour before or for 2 to 6 hours after Cilaxoral administration, a specific condition designed to prevent the malabsorption of other drugs. This structured protocol dictates the correct intake environment and prevents prolonged use.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies for Cilaxoral (Sodium Picosulfate)

The available research evidence for Cilaxoral describes two main areas that have been explored by studies. This summary focuses on the types of studies that have been conducted, the outcomes measured in those studies, and the limitations noted by researchers and regulatory bodies.


Evidence for Short-Term Management of Functional Constipation

The research examined studies related to functional constipation primarily involves controlled clinical trials. Scientists conducted short-term randomized, double-blind, placebo-controlled trials (RCTs) to explore how symptoms change over time when compared to an inactive substance.

These studies focused on precise measurements of bowel function. Researchers examined the frequency of Complete Spontaneous Bowel Movements (CSBMs) per week and monitored outcomes related to patient-reported experiences, tracking measures like constipation-related Quality of Life (QoL) and physical discomfort. The populations studied in this research were mainly adults diagnosed with chronic functional constipation.

Short-term RCTs reported findings related to measurements of CSBMs per week when comparing the observed groups. Research contributes to understanding short-term symptom patterns by contextualizing how patients reported their experience during the trial period.

Evidence for Bowel Cleansing in Preparation for Procedures

Research regarding the use of Cilaxoral for preparing the bowel prior to medical procedures, such as colonoscopy, was evaluated in clinical trials. These studies were often designed as active-comparator trials, meaning they explored the comparative measurements against other standard cleansing solutions, rather than against a placebo. The main focus of these trials was on the measurements of colon visualization.

Comparative trials reported measurements of preparation adequacy scores, documenting the proportion of patients reaching an adequate level of clearance for the procedure. Findings describe patterns observed in the studies related to patient reported experience, including satisfaction and the perceived ease of consuming the preparation.

Key Gaps and Remaining Research Uncertainties

Long-term effects are not fully established, as most controlled trials utilized follow-up durations that were limited to acute or short-term periods. Comparative evidence is lacking for certain clinical scenarios, and data for certain groups remain insufficient. Overall, research provides context on group patterns, but it does not determine whether an individual will respond similarly, as results apply only to the populations studied under the specific conditions of the clinical trials.

Key Studies & References Public Assessment Report of over-the-counter stimulant laxatives: benefit-risk review (Sodium Picosulfate) - GOV.UK

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Cilaxoral (FAQ)

Q: How quickly does Cilaxoral usually start to work?

A: Official information indicates that the expected onset of action, meaning the time it takes for the medicine to start having an effect, typically occurs within 6 to 12 hours after it is administered. This time frame corresponds with the general administration instruction to take it at bedtime.

Q: How long does the effect of Cilaxoral last in the body?

A: Regulatory information explains that only a small amount of the active part of the medicine is absorbed into the bloodstream. This active part is then processed by the body, almost completely changed into other forms, and then excreted. About 10% of the dose is typically found in the urine up to 48 hours later.

Q: Is Cilaxoral the same type of medicine as others that treat the same condition?

A: Cilaxoral contains the active ingredient sodium picosulfate, which is formally classified as a stimulant laxative. This classification indicates that it works differently from other classes of medicines used for the same purpose, such as bulk-forming agents or osmotic laxatives, which have distinct mechanisms of action described in official documents.

Q: Why do people sometimes mention feeling tired after starting Cilaxoral?

A: Tiredness, or fatigue, is listed as an uncommon side effect in regulatory documents for some products containing sodium picosulfate. Changes in energy levels are best addressed by consulting a healthcare professional.

Q: Are there studies about the long-term use of Cilaxoral?

A: Controlled clinical trials that provide evidence for this medicine typically focus on short-term periods, such as a few days or weeks. Regulatory summaries indicate that high-quality, long-term studies exploring the effects of continuous use over many months are generally limited.

Q: Does Cilaxoral affect the ability to drive or operate machinery?

A: Official product information advises caution before driving or operating machinery. Some potential side effects, such as dizziness or feeling faint, may temporarily affect a person's concentration and ability to perform these tasks.

Q: What are the most common side effects mentioned in research on Cilaxoral?

A: The common side effects documented in official sources include gastrointestinal issues such as stomach pain or cramps, nausea, vomiting, and bloating. Headaches are also frequently listed as a common adverse event.

Q: Is Cilaxoral a controlled substance?

A: No, the active ingredient in Cilaxoral, Sodium Picosulfate, has not been classified as a scheduled controlled substance by regulatory bodies in the United States or other major regions.

Q: Is there a generic version of Cilaxoral available?

A: The active ingredient, Sodium Picosulfate, is available in multiple generic products under various brand names. However, specific combination products (those that contain sodium picosulfate plus other ingredients) may not yet have a generic equivalent approved by regulatory agencies.

Q: What happens if a dose of Cilaxoral is missed?

A: Official patient instructions generally describe taking the missed dose as soon as it is remembered. However, if it is almost time for the next scheduled dose, the instruction is typically to skip the missed dose and resume the regular schedule. Official guidance states that doubling the dose to compensate for a missed one is not recommended.

Q: Are there known issues with taking Cilaxoral if I have existing kidney problems?

A: Yes, regulatory documents strictly state that use is contraindicated (prohibited) for patients with severe reduced renal function (severe kidney problems). Caution is also advised for patients with mild or moderate kidney impairment due to the risk of accumulation of one of the product’s components.

Q: Is it normal to experience mild stomach upset when first taking Cilaxoral?

A: Yes, gastrointestinal symptoms such as abdominal pain, nausea, and bloating are documented as common side effects associated with the medicine. These may occur when an individual first begins taking the preparation as the body adjusts to the changes in intestinal activity.

Q: Can I stop taking Cilaxoral immediately, or does it require a gradual change?

A: For short-term constipation relief, the medicine is intended for use over a limited duration, often no more than five consecutive days. Once regular bowel function resumes, the regulatory protocol describes that the dose is typically reduced and can then be stopped without a mandated tapering process.

Q: How does Cilaxoral compare to other treatments in clinical trial outcomes?

A: Clinical studies have been conducted that examine Cilaxoral against other preparations used for the same conditions, such as for bowel cleansing prior to a procedure. These trials document outcomes like the percentage of patients reaching adequate colon cleansing levels or patient-reported measures compared between the groups studied.

Q: Is Cilaxoral associated with any rare but serious side effects?

A: Yes, official warnings and adverse event reports include serious and clinically significant reactions. These include the potential for severe fluid and electrolyte imbalance, which may lead to complications such as seizures or heart rhythm issues, as well as severe allergic reactions.

Q: Can Cilaxoral cause changes in mood or sleep?

A: Sleep disturbances have been noted in some clinical trials involving this medication. Furthermore, the common side effects of headaches and dizziness are known to sometimes affect a person's overall sense of well-being, which could influence mood or sleep patterns.

Q: Can Cilaxoral be used during pregnancy, according to official guidelines?

A: Official regulatory guidance advises that the medicine should not be taken during pregnancy. Use is only permitted if a healthcare provider determines that the expected benefit to the patient is clearly greater than any possible risk to the developing fetus.

Q: Is Cilaxoral safe to use while breastfeeding, according to regulatory bodies?

A: Similar to pregnancy, regulatory guidance advises that the medicine should not be taken while breastfeeding. Use is generally restricted to situations where a healthcare provider determines that the expected benefit to the mother clearly outweighs any possible risk to the nursing infant.

Q: Do any official sources mention a risk of dependence with Cilaxoral?

A: Official warnings describe that prolonged or continuous daily use of laxatives is generally not advised. Regulatory bodies state that exceeding the recommended duration may lead to dependence on the laxative for a normal bowel movement.

Q: Are there specific patient groups that are generally excluded from using Cilaxoral?

A: Yes, patient use is strictly prohibited (contraindicated) for individuals with several critical medical conditions. These include gastrointestinal obstruction (a blockage in the intestines), bowel perforation, toxic megacolon, and severe dehydration.

Q: What is the maximum duration for which Cilaxoral is typically studied?

A: The clinical trials that provide evidence for the medication were primarily limited to short-term follow-up periods. For example, studies for constipation were often limited to a few weeks, and trials for bowel cleansing were single-use regimens.

Q: Is Cilaxoral known to cause headaches?

A: Yes, headaches are specifically listed among the common side effects documented in official regulatory sources and patient information leaflets for this medicine.

Q: Do official documents mention any potential interactions with common vitamins?

A: Official documents warn that accelerated intestinal transit can reduce the absorption of other oral medications. Therefore, regulatory sources generally advise separating the time of taking Cilaxoral from the time of taking all other oral medications, including supplements and vitamins, by a specified interval.

Q: Are there any special considerations for people with liver impairment using Cilaxoral?

A: Regulatory information and warnings primarily focus on the risk to patients with kidney impairment. Use in the presence of liver issues is a matter for consultation with a healthcare professional.

Q: What are the official recommendations if a person experiences an allergic reaction to Cilaxoral?

A: Official patient instructions describe that seeking immediate medical attention or contacting a healthcare provider is the general recommendation. This is necessary if a person develops signs of a serious allergic reaction, such as swelling of the face, tongue, or throat, or difficulty breathing.

Q: Does Cilaxoral carry a special warning from the FDA or similar agency?

A: Yes, regulatory bodies require specific special warnings regarding the risk of serious fluid and electrolyte imbalance. This condition can potentially lead to severe complications, such as cardiac arrhythmia (an irregular heartbeat), especially in patients already considered to be at risk.

Q: Can taking Cilaxoral affect blood tests?

A: Official patient information for some products indicates that a healthcare provider should be informed if blood tests are planned. This is because the changes in fluid and electrolyte levels caused by the medicine may interfere with the results of certain laboratory tests.

Q: Does Cilaxoral interact with birth control pills?

A: Regulatory documents include a warning that the accelerated transit of intestinal content can potentially reduce the absorption and therefore the effectiveness of other oral medications. This category of medicines includes hormonal contraceptives, and careful timing separation is advised.

Q: Are there different strengths or forms of Cilaxoral?

A: Yes, the medicine is manufactured and made available in different pharmaceutical forms. This includes oral solution, drops, and tablets, and these forms may be offered in various strengths depending on the product and its approved indication in a given region.

Q: Can Cilaxoral be taken by people who are elderly?

A: Use is not prohibited in elderly people, but official warnings advise caution. Patients over 55 are listed as being at increased risk for certain harmful side effects, such as severe electrolyte imbalance, and should be monitored closely during treatment.

Q: What is the difference between Cilaxoral and other similar medicines described in official documents?

A: Cilaxoral contains a stimulant laxative that works by directly increasing muscle contractions in the colon. This mechanism is different from that of bulk-forming (fiber) laxatives that absorb water, or osmotic laxatives that draw water into the colon, each of which is described separately in official documents.

Q: Does Cilaxoral have to be taken at a specific time of day?

A: For the treatment of constipation, official instructions generally recommend taking the dose once daily at bedtime. This specific timing is usually suggested to help the 6- to 12-hour onset of action align with a bowel movement the following morning.

Q: What evidence exists regarding Cilaxoral's effectiveness?

A: Clinical trials have been conducted to explore the medicine's effect compared to a placebo or other treatments. The measurements reported in these studies include outcomes such as the change in complete spontaneous bowel movements (CSBMs) per week for constipation and the adequacy of colon visualization scores for bowel preparation.

Q: Is Cilaxoral considered a common treatment option?

A: Sodium Picosulfate is a widely used ingredient and is classified as a recognized product in major medical compendia for the treatment of constipation. Its use is established for providing focused assistance in promoting bowel movement.

Q: Are there any special warnings for people with a history of heart issues taking Cilaxoral?

A: Yes, official warnings advise caution for patients with a history of heart issues. Specifically, those at increased risk of serious cardiac arrhythmias (irregular heart rhythm) should be monitored due to the potential for severe fluid and electrolyte imbalances caused by the medicine.

Advertisements

How should Cilaxoral be stored and disposed of?

How to Store and Dispose of Cilaxoral

Official regulatory guidelines require that sodium picosulfate-containing products like Cilaxoral be stored under specific conditions to maintain stability. The medicine must be kept in its original package and stored away from light, heat, and moisture.

Storage Requirements

Condition Requirement
Temperature Do not store above 25°C (Controlled room temperature).
Container Keep in the original package or outer carton (for oral solution).
Stability Any portion of the product, particularly after a sachet is opened or reconstituted, must be used immediately and discarded.

For safety, the product must be stored out of the sight and reach of children.

Disposal

All unused or expired medicine must be disposed of in accordance with local requirements; do not dispose of the product via wastewater or household waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Cilaxoral found in:

A-Z Index: